SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is rallying as the community anticipates significant recognition for its groundbreaking cancer therapies, spurred by Dr. Patrick Soon-Shiong's compelling presentations and extreme short interest fueling discussions of an imminent squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to intense community debate surrounding Donald Trump's State of the Union address, as many speculate whether the speech will ignite a rally, given the stock often acts as a proxy for his political sentiment, or further its decline amid discussions of his legal issues and economic policies.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is at the center of market attention ahead of its highly anticipated Q4 earnings report, with community discussion intensely focused on whether a potential blowout performance will propel the stock to new highs or trigger a "sell the news" event. This uncertainty is heightened by ongoing debates about AI spending, market maker influence, and concerns over China export controls.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as the community speculates intensely on potential market-moving comments from a political address, while also closely watching an upcoming major AI chipmaker's earnings report for broader market direction.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending after reporting mixed Q4 results, which showed increased revenue but also widening losses and substantial cash burn, fueling community debate over its long-term viability. The market is weighing future model launches and recent layoffs against persistent dilution concerns and the financial backing of the Saudi Public Investment Fund.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a high-stakes bidding war for Warner Bros. Discovery, as WBD's board deems a higher Paramount Skydance offer potentially superior, giving Netflix a four-day window to respond. The community is fiercely debating if Netflix should raise its bid, risking further dilution, or walk away to collect a significant breakup fee, with added political scrutiny impacting the decision.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending following its earnings report, which showcased strong revenue growth and new restaurant openings for fiscal 2025, alongside a positive outlook for fiscal 2026. The community is actively debating its high valuation and moderated same-store sales growth against its aggressive expansion strategy and perceived market share gains over competitors like Chipotle.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending after strong earnings were met with lower-than-expected 2026 sales guidance, triggering a sharp sell-off and community debate over the outlook, with bulls highlighting its U.S. manufacturing and competitive edge for growing energy demand, while bears focus on the near-term revenue concerns.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computer, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Environmental Technologies segment focuses on manufacturing ceramic substrates and filter products for emissions control in mobile applications. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is experiencing a significant rally as escalating demand for its fiber optic solutions positions it as a critical infrastructure play for the accelerating buildout of AI data centers. The community is actively discussing a major agreement to supply a hyperscaler, anticipating additional similar deals, even as some caution about its rapid ascent and overbought indicators.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending following its recent earnings report, which included softer-than-expected subscription revenue guidance and an immediate CEO change aimed at accelerating AI transformation, intensifying the ongoing debate among investors. The community is sharply divided, with many questioning Workday's valuation and the broader enterprise software sector's growth trajectory amidst concerns about AI disruption and the use of non-GAAP financial metrics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AC Immune (NASDAQ:ACIU) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of AC Immune from a "hold" rating to a "sell" rating in a research note on Saturday...

AC Immune (NASDAQ:ACIU) Stock Price Down 5.4% - Time to Sell?

AC Immune (NASDAQ:ACIU) Trading Down 5.4% - Here's Why...

Short Interest in AC Immune (NASDAQ:ACIU) Grows By 94.4%

AC Immune (NASDAQ:ACIU - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 3,593,227...

AC Immune (NASDAQ:ACIU) Trading Up 5% - Should You Buy?

AC Immune (NASDAQ:ACIU) Trading 5% Higher - Here's What Happened...

<ul class="summary-bullets"><li>The trial results showed for the first time that active immunotherapy targeting a-syn pathology could slow the progression of Parkinson’s disease.&nbsp;</li><li>The interim results from the study showed a 100% responder rate for all targets.</li><li>ACIU plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp; &nbsp;</li></ul>AC Immune SA (ACIU) shares surged on Thursday morning after the biopharma company announced positive results from the interim Phase 2 study of its early Parkinson’s disease treatment.&nbsp;The company said that the results of the VacSYn trial of ACI-7104.056 showed, for the first time, that targeting a-syn pathology with an active immunotherapy could possibly slow the progression of Parkinson’s disease.&nbsp;Shares of&nbsp;<a href="https://stocktwits.com/symbol/ACIU">ACIU</a> surged over 23% in pre-market trading after the announcement.&nbsp;“The interim Phase 2 data shows the potential of our ACI-7104.056 active immunotherapy to slow the progression of Parkinson’s disease and hold the promise of a tremendous step forward for millions of patients,” said Andrea Pfeifer, CEO of AC Immune SA. Pfeifer added that the strong results would be a basis for accelerating the development of the treatment.&nbsp;<h2 class="st-heading-2">Study Results</h2>The interim results from the study showed that the company’s new treatment had a 100% responder rate, meaning all participants had the expected immune response across all immunogenicity measures used.There were no clinically relevant or serious adverse effects to the drug apart from routine side effects such as injection site reactions, headaches, and fatigue, as reported by some participants.&nbsp;Final results from the Part 1 trial are expected in mid-2026, and the company plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp;<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around ACIU jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1282/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_7_36_27_PM_png_161653af50.webp" alt="ACIU sentiment and message volume" width="1282" height="158"></figure>Shares of ACIU are up over 31% in the past six months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is AC Immune Stock Up Over 23% Today?

ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 

Equity

FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC...

FY2025 EPS Estimates for AC Immune Raised by Leerink Partnrs

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AC Immune in a research note issued on Wednesday, November...

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$2.72
Prev Close	$2.53
Open	$2.55
Dividend Yield	0.00%
50-Day Moving Average	$3.21
Beta	0.99
Avg. Volume	418,749.35
PE Ratio	-3.00

52-Week High	$4.00
52-Week Low	$1.43
Market Capitalization	$266.07M
EPS (Annual)	-$0.5799
Price to Book	2.84
Revenue Per Employee	$180,287.39

ACIU
AC Immune SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACIU News

ACIUAC Immune SA